Blog

How far along are you in realizing benefits from automation? What is the biggest hindrance in adopting automation technologies? This two-part blog series analyzes polling responses from a recent DIA webinar and shares ArisGlobal’s thoughts on practical use cases for automation in pharmacovigilance and regulatory.

What is the greatest challenge across end-to-end pharma processes? How would you rate your automation capabilities? This two-part blog series analyzes attendee polling responses from a recent DIA webinar and shares ArisGlobal’s thinking about practical use cases for automation in pharmacovigilance and regulatory.

LifeSphere Regulatory platform offers unified modules for regulatory information management, IDMP/compliance management, and regulatory submissions tracking. Watch this newscast and discover how LifeSphere Regulatory platform offers innovative end-to-end approach for pharmaceutical regulatory affairs.

Preparing to meet regulatory and commercial demands of the future requires a progressive, future-proof approach. As the regulatory department prepares…

One of the key roles of pharmacovigilance departments is to understand the benefit-risk profile of a drug. But departments are often bogged down by manual tasks that can absorb time, which might be better spent on value-centric activities. Perhaps the most tedious pharmacovigilance activity is medical literature monitoring (MLM), and as we discussed in our last blog, manual, repetitive tasks are a primary cause of employee dissatisfaction.

During a recent webcast, ArisGlobal carried out an insightful survey, which found that visibility and reporting inefficiencies remain a headache.

Pharmacovigilance is at a crossroads. The best, most innovative way forward for PV departments may well be automation, as they address the challenges (or market pull factors) and opportunities (or technology push capabilities).

As a medical information software provider, it is necessary to recognize that there is some decent software out there in the life science’s space

This is the second in a three-part blog series on National Pharmacovigilance systems and the role of technology in bridging the gaps in pharmacovigilance of regulatory authorities around the world.

As evident from our second polling question, ”How far along the road would you say you are for a ‘new’ technological revolution,” the journey to capitalize on the next industrial revolution is just beginning for most participants